A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests.

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Using the ‘golden key’ to identify suitable patients, the results from the trial indicate that deaths could be cut by a third ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, a study has ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...